Vijay Pande on running a small fund after running A16Z's $4B bio fund (techcrunch.com)

Vijay Pande, the former head of Andreessen Horowitz's $4 billion bio fund, has transitioned to a more focused investment approach with his new firm, VZVC. Co-founded with Zach Werner, VZVC centers on a select few concentrated investments each year, leveraging AI heavily to streamline operations. This pivot reflects a shift in the biotech landscape where AI can enhance drug discovery, with Pande arguing that biological data's uniqueness—often locked behind proprietary datasets—poses both challenges and opportunities for fostering innovative solutions in precision medicine. Pande highlights the evolution of biology from a "science of discovery" to one that can be engineered through AI. While advancements may reduce costs in drug development and clinical trials, the inherent unpredictability remains, as traditional animal models often fall short in predicting human responses. VZVC's concentrated investment strategy aims to support long-term partnerships with trustworthy founders, promoting collaboration over competition in an industry increasingly reliant on AI and robust data sharing. As Pande navigates this new landscape, he emphasizes the need for foundational biological models to fuel breakthroughs, moving beyond the hype surrounding AI's capabilities to address its limitations in data scarcity.